Characteristics and outcomes of acute myelogenous leukemia patients with very late relapse (>5 years)
Characteristics and outcomes of acute myelogenous leukemia patients with very late relapse (>5 years)
复制标题
极晚期复发（>5年）急性髓性白血病患者的特征和结局
作者：
B. Medeiros;M. Minden;A. Schuh;A. Schimmer;K. Yee;J. Lipton;H. Messner;Vikas Gupta;K. Chun;W. Xu;P. Das;S. Kamel‐Reid;J. Brandwein
描述了15例急性髓性白血病（AML）患者的临床特征和结局，这些患者在诱导完全缓解后至少5年复发（极晚期复发AML）。该亚组占同期在该机构观察到的所有复发患者的3%。该队列中有8名男性，诊断时的中位年龄为48岁（范围13 - 77岁）。9例患者具有M4/M5法国-美国-英国（FAB）分类亚型，大多数具有中等风险细胞遗传学。首次完全缓解（CR-1）的中位持续时间为9年（范围5.2 - 11.5年）。13例患者（86%）在再诱导治疗后达到CR-2。该队列的5年无复发生存率和总生存率分别为59%和51%。我们的结论是，极晚期复发的AML是一种罕见的事件，在这些患者中的再诱导与非常高的CR率和潜在的治愈分数相关。
The clinical characteristics and outcome of 15 patients with acute myelogenous leukemia (AML) who experienced relapse at least 5 years after induction of complete remission (very late-relapse AML) are described. This subgroup represented 3% of all relapsed patients seen at this institution over the same time period. There were eight males in this cohort and the median age at diagnosis was 48 years (range 13 – 77 years). Nine patients had M4/M5 French – American – British (FAB) classification subtype and most had intermediate risk cytogenetics. The median duration of first complete remission (CR-1) was 9 years (range 5.2 – 11.5 years). Thirteen patients (86%) achieved CR-2 with reinduction therapy. The 5-year relapse-free survival and overall survival rates of this cohort were 59% and 51%, respectively. We conclude that very late-relapse AML is a rare event, and that reinduction in these patients is associated with very high CR rates and a potential cure fraction.